Biotech firm Biocon will make equity investment in Vaccinex Inc. and said it has tied up with the US firm to discover and develop therapeutic antibody products for cancer, inflammation and autoimmune diseases.

As part of the collaboration, Biocon would make an equity investment in Vaccinex and both the companies would jointly work to identify at least four therapeutic antibody products, Biocon informed the Bombay Stock Exchange on Thursday.

"We are delighted to announce this partnership as Vaccinex has a strong discovery-led platform that will be beneficial to Biocon," Kiran Mazumdar-Shaw, chairman and managing director, Biocon, said.

The partnership would provide biotechnology solutions worldwide, she said.

The collaboration combines Vaccinex's capabilities to discover antibodies using its proprietary antibody discovery technology and Biocon's expertise in clinical research and biologics manufacturing.